DDrare: Database of Drug Development for Rare Diseases

221. 抗糸球体基底膜腎炎
［臨床試験数：1，薬物数：3（DrugBank：1），標的遺伝子数：0，標的パスウェイ数：0］

Searched query = "Anti-glomerular basement membrane disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03157037 (ClinicalTrials.gov)	March 1, 2017	11/5/2017	An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES)	An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES	Anti-Glomerular Basement Membrane Disease	Biological: HMed-IdeS	Mårten Segelmark	Hansa Biopharma AB	Completed	18 Years	N/A	All	15	Phase 2	Austria;Czechia;Denmark;France;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03157037
(ClinicalTrials.gov)

March 1, 2017

11/5/2017

An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES)

An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES

Anti-Glomerular Basement Membrane Disease

Biological: HMed-IdeS

Mårten Segelmark

Hansa Biopharma AB

Completed

18 Years

N/A

All

Phase 2

Austria;Czechia;Denmark;France;Sweden